Novo Nordisk A/S has announced plans to increase its commitment to cell-based therapies following the achievement of preclinical proof-of-concept for a cell therapy to treat Type 1 diabetes. The diabetes therapy, in which pluripotent stem cells are used to generate insulin-producing beta cells, is expected to enter human trials “within the next few years,” the company said on 16 May.
